Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

Keyphrases

• Hyperkinetic Movement Disorders 100%
• Tetrabenazine 100%
• Dystonia 36%
• Tardive Dyskinesia 36%
• Huntington's Chorea 27%
• United States 18%
• Tolerability 18%
• Huntington's Disease 18%
• Tic Disorders 18%
• Database Search 9%
• Adverse Effects 9%
• Pediatric 9%
• Pediatric Population 9%
• English Language 9%
• Isozymes 9%
• Clinical Benefit 9%
• Adult Patients 9%
• VMAT2 9%
• Pediatric Patients 9%
• Monoamines 9%
• Clinical Application 9%
• Parkinsonism 9%
• Age-related 9%
• Cochrane Library 9%
• PubMed 9%
• Randomized Double-blind Placebo-controlled Study 9%
• Clinical Efficacy 9%
• Somnolence 9%
• Active Metabolite 9%
• Phonic Tic 9%
• Motor Tics 9%
• Tourette Syndrome 9%
• Clinical Role 9%
• Off-label Use 9%
• Oral Therapy 9%
• Adult Population 9%
• Cytochrome P450 2D6 (CYP2D6) 9%
• Blinded Study 9%
• Central Dopamine 9%
• Clinical Database 9%
• Embase 9%
• Chorea 9%
• Pharmacology Studies 9%
• Alternative Agents 9%
• First-pass Metabolism 9%
• Hyperkinetic Movements 9%
• Gilles De La Tourette Syndrome 9%
• Orphan Disease 9%
• MedlinePlus 9%
• Subject Terms 9%

Medicine and Dentistry

• Stereotypic Movement Disorder 100%
• Tetrabenazine 100%
• Huntington's Disease 45%
• Tardive Dyskinesia 36%
• Pediatrics 27%
• Dystonia 27%
• Prospective Study 18%
• Tic Disorder 18%
• Diseases 9%
• Clinical Trial 9%
• Adverse Effect 9%
• English (Language) 9%
• Retrospective Study 9%
• Placebo-Controlled Study 9%
• Parkinsonism 9%
• Isoenzyme 9%
• Somnolence 9%
• Off-Label Use 9%
• Chorea 9%
• CYP2D6 9%
• Active Metabolite 9%
• First Pass Effect 9%
• Orphan 9%
• Dystonic Disorder 9%
• Vesicular Monoamine Transporter 2 9%
• Monoamine 9%
• Gilles De La Tourette Syndrome 9%
• MedlinePlus 9%
• Oral 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Motor Dysfunction 100%
• Tetrabenazine 100%
• Huntington Chorea 45%
• Tardive Dyskinesia 36%
• Tic 36%
• Dystonia 27%
• Prospective Study 18%
• Tolerability 18%
• Clinical Trial 9%
• Diseases 9%
• Isoenzyme 9%
• Vesicular Monoamine Transporter 2 9%
• Retrospective Study 9%
• Placebo-Controlled Study 9%
• Somnolence 9%
• Active Metabolite 9%
• Monoamine 9%
• Parkinsonism 9%
• Off-Label Use 9%
• First Pass Effect 9%
• Chorea 9%
• Dystonic Disorder 9%
• CYP2D6 9%
• Gilles De La Tourette Syndrome 9%